A Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL.

This is a global, multicenter, randomized, open-label, Phase III confirmatory study to investigate the efficacy and safety of Lisaftoclax (APG-2575) in combination with Acalabrutinib in patients with newly diagnosed CLL/SLL.

Trial Details

NCT ID
NCT06319456
Phase
PHASE3
Sponsor
Ascentage Pharma Group Inc.
Status
RECRUITING
Cancer Type
Chronic Lymphocytic (CLL) Leukemia
Interventions
  • Lisaftoclax (APG-2575)
  • Acalabrutinib
  • Fludarabine
  • Cyclophosphamide,CTX
  • Rituximab
  • Chlorambucil
Locations (sample)
  • Bengbu, Anhui, China|32.94083,117.36083
  • Guangzhou, Guangdong, China|23.11667,113.25
  • Guangzhou, Guangdong, China|23.11667,113.25
  • Zhanjiang, Guangdong, China|21.23391,110.38749
  • Zhengzhou, Henan, China|34.75778,113.64861

Key Eligibility Criteria

  • CLL/SLL must be diagnosed according to the IWCLL NCI-WG Guidelines (2018 edition) and meet at least one of the criteria requiring treatment.
  • With a measurable disease.
  • ECOG score 0-2.
  • QTcF interval: ≤450ms in males, ≤470ms in females.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Chronic Lymphocytic (CLL) Leukemia Trials on Trialify →